Drug Profile
SANORG 32701
Alternative Names: SR 32701Latest Information Update: 08 Jan 2001
Price :
$50
*
At a glance
- Originator Organon; Sanofi-Synthelabo
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 08 Jan 2001 Discontinued-I for Thrombosis in Europe (Injection)
- 08 Jan 2001 Discontinued-I for Thrombosis in USA (Injection)
- 27 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo